SMN2 and proximal spinal muscular atrophy: It was initially developed as a therapeutic for children with spinal muscular atrophy (SMA) as it modulates splicing of the poorly-spliced survival motor neuron 2 (SMN2) gene and restores full-length SMN2 transcript and SMN protein levels to normal10.